The Goldilocks Time for Remdesivir — Is Any Indication Just Right?

Abstract

Multiple myeloma is a cancer of plasma cells that has an estimated incidence of 26,850 new patients in 2015 in the United States.(1) In the past few years, dramatic progress has been made in the treatment of this disease. New classes of drugs, including proteasome inhibitors (e.g., bortezomib and carfilzomib) and immunomodulatory agents (e.g., lenalidomide and pomalidomide), have improved response rates and survival significantly, and it now appears that immunotherapy is likely to lead to even greater advances. Results regarding the use of daratumumab, an antibody directed against CD38, in patients with relapsed, refractory multiple myeloma are now reported in . . .